Ligand Pharmaceuticals Incorporated (LGND)
Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price
on Jul 2, 2025
Ligand Pharmaceuticals Analyst Ratings
Total Analysts
8
Consensus Rating
Strong Buy
Price Target
$144.71
Upside
+27.72%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $142 → $145 | Buy | Maintains | $142 → $145 | +27.98% | May 9, 2025 |
| Stifel | Stifel | Strong Buy Initiates $143 | Strong Buy | Initiates | $143 | +26.21% | Apr 10, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +19.15% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +41.22% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +26.21% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +23.57% | Nov 12, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $110 → $135 | Strong Buy | Maintains | $110 → $135 | +19.15% | Nov 8, 2024 |
| Barclays | Barclays | Buy Maintains $125 → $150 | Buy | Maintains | $125 → $150 | +32.39% | Nov 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $135 → $147 | Buy | Maintains | $135 → $147 | +29.74% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $157 | Strong Buy | Reiterates | $157 | +38.57% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $157 | Strong Buy | Reiterates | $157 | +38.57% | Oct 31, 2024 |
| Barclays | Barclays | Buy Maintains $110 → $125 | Buy | Maintains | $110 → $125 | +10.33% | Oct 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $144 → $157 | Strong Buy | Maintains | $144 → $157 | +38.57% | Oct 21, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $135 | Buy | Initiates | $135 | +19.15% | Oct 3, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $95 → $110 | Strong Buy | Maintains | $95 → $110 | -2.91% | Aug 12, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.